Abstract
Background: Despite recent advances in improved glycemic control, the magnitude of lifetime risk from premature cardiovascular disease in individuals with type 1 diabetes remains at least 10 fold higher than in the general population. The availability of lipoprotein fractionation has allowed the spotlight for this increased risk to shift from dysglycemia to diabetes-induced dyslipidemia associated with insulin resistance. Interventions designed to simultaneously improve both factors can have distinct and additive effects on slowing the initiation and progression of atherosclerotic lesions. As fullblown cardiovascular disease is not evident during childhood, there is a critical need to identify the most predictable surrogate markers that could assign elevated risk, as well as the design of safe and targeted interventions that could improve outcomes in this population.
Conclusion: This review will examine the evidence supporting the notion that cardiovascular disease in type 1 diabetes is associated with significant insulin resistance and it begins in childhood, making it necessary to design rational clinical trials that will significantly reduce risk in this population.
Keywords: Cardiovascular disease, dyslipidemia, HbA1c, insulin resistance, lipoproteins, statins, systematic review, type 1 diabetes.
Current Diabetes Reviews
Title:Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Volume: 13 Issue: 6
Author(s): Jose A. Canas, Samuel S. Gidding and Nelly Mauras*
Affiliation:
- Pediatric Endocrinology, Diabetes & Metabolism, Nemours Children's Health System, 807 Children's Way, Jacksonville, FL 32207,United States
Keywords: Cardiovascular disease, dyslipidemia, HbA1c, insulin resistance, lipoproteins, statins, systematic review, type 1 diabetes.
Abstract: Background: Despite recent advances in improved glycemic control, the magnitude of lifetime risk from premature cardiovascular disease in individuals with type 1 diabetes remains at least 10 fold higher than in the general population. The availability of lipoprotein fractionation has allowed the spotlight for this increased risk to shift from dysglycemia to diabetes-induced dyslipidemia associated with insulin resistance. Interventions designed to simultaneously improve both factors can have distinct and additive effects on slowing the initiation and progression of atherosclerotic lesions. As fullblown cardiovascular disease is not evident during childhood, there is a critical need to identify the most predictable surrogate markers that could assign elevated risk, as well as the design of safe and targeted interventions that could improve outcomes in this population.
Conclusion: This review will examine the evidence supporting the notion that cardiovascular disease in type 1 diabetes is associated with significant insulin resistance and it begins in childhood, making it necessary to design rational clinical trials that will significantly reduce risk in this population.
Export Options
About this article
Cite this article as:
Canas A. Jose, Gidding S. Samuel and Mauras Nelly*, Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes, Current Diabetes Reviews 2017; 13 (6) . https://dx.doi.org/10.2174/1573399813666170113142621
DOI https://dx.doi.org/10.2174/1573399813666170113142621 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Current and Future Insights in H. pylori Eradication Regimens: The Need of Tailoring Therapy
Current Pharmaceutical Design Clinical Utility of Microarrays: Current Status, Existing Challenges and Future Outlook
Current Genomics Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC
Current Stem Cell Research & Therapy Traditional Chinese Medicine - Sea Urchin
Mini-Reviews in Medicinal Chemistry Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Current Applications of Therapeutic Gases in Neonatal Intensive Care
Current Pediatric Reviews A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders Correlates of Physical Activity of Children and Adolescents with Visual Impairments: A Systematic Review
Current Pharmaceutical Design Is there an Association Between Periodontitis and Atherosclerosis in Adults? A Systematic Review
Current Vascular Pharmacology microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets Developments in Non-Surgical Therapies for Abdominal Aortic Aneurysm
Current Vascular Pharmacology Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study
Current Vascular Pharmacology Serendipity of Erythromycin in the Management of Periprosthetic Inflammation
Current Drug Therapy Simultaneous Determination of Six Components in Jingzhiguanxin Tablet by High-Performance Liquid Chromatography
Current Pharmaceutical Analysis An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors
Current Drug Metabolism